CD248 (E9Z7O) XP® Rabbit mAb #47948
- WB
- IP
- IHC
- IF
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 190 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| IHC Leica Bond | 1:100 - 1:400 |
| Immunohistochemistry (Paraffin) | 1:100 - 1:400 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:400 |
Storage
For a carrier free (BSA and azide free) version of this product see product #68864.
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro403 of human CD248 protein.
Background
CD248, also known as Endosialin and TEM1, is a stromal cell marker expressed on activated mesenchymal cells including fibroblasts and pericytes. Not normally detectable in most adult tissues, it is highly expressed in lymphoid tissues during development, and in disease states where increased stromal cell proliferation and migration are evident (1-3). CD248 is known to be upregulated in breast cancer, brain tumors (4-6), and other malignancies including sarcoma (12), and it has been implicated in sprouting angiogenesis and vasculogenesis (7). It is thought that the CD248 gene is upregulated in response to hypoxic conditions in the tumor environment through HIF2 activation (8). Interestingly, CD248 is found to be highly expressed in activated fibroblasts. In liver fibrosis for example, CD248 marks the Hepatic Stellate Cells, the activated cells responsible for matrix production (9,10). In kidney fibrosis, CD248 marks the key effector cells within the fibrotic stroma including pericytes, myofibroblasts, and stromal fibroblasts (11), and in Idiopathic Pulmonary Fibrosis, CD248 may be a marker for severity of disease (12). CD248 has become a target of interest for pharmaceutical intervention in a wide scope of diseases (13).
- Lax, S. et al. (2010) Eur J Immunol 40, 1884-9.
- Lax, S. et al. (2007) FEBS Lett 581, 3550-6.
- Dolznig, H. et al. (2005) Cancer Immun 5, 10.
- Viski, C. et al. (2016) Cancer Res 76, 5313-25.
- Simonavicius, N. et al. (2008) Mod Pathol 21, 308-15.
- Carson-Walter, E.B. et al. (2009) BMC Cancer 9, 417.
- Kontsekova, S. et al. (2016) Neoplasma 63, 183-92.
- Ohradanova, A. et al. (2008) Br J Cancer 99, 1348-56.
- Wilhelm, A. et al. (2016) Gut 65, 1175-85.
- Mogler, C. et al. (2015) EMBO Mol Med 7, 332-8.
- Smith, S.W. et al. (2011) Kidney Int 80, 199-207.
- Bartis, D. et al. (2016) BMC Pulm Med 16, 51.
- Teicher, B.A. (2019) Oncotarget 10, 993-1009.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专